Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INSMED IncINSM · Entity 3174 | Director · Chair and CEO | July 23, 2026 | July 24, 2026 |
| NewAmsterdam Pharma Co N.V.NAMS · Entity 1826 | Director | January 07, 2026 | January 10, 2026 |
| uniQure N.V.QURE · Entity 4162 | Director | January 27, 2017 | January 31, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INSMED Inc
Report date July 23, 2026 · Filed July 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 259,058 |
Ending reported balance
After 2026-07-23 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-07-23 · Exercise / conversion · Acquired 6,260 · Balance 265,318 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Row 2 · 2026-07-23 · Exercise / conversion · Acquired 4,440 · Balance 269,758 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Row 3 · 2026-07-23 · Sale · Disposed 4,828 · Balance 264,930 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2: This is the weighted average sales price representing 4,828 shares sold at prices ranging from $105.09 to $106.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Row 4 · 2026-07-23 · Sale · Disposed 5,872 · Balance 259,058 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3: This is the weighted average sales price representing 5,872 shares sold at prices ranging from $106.09 to $106.78 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.46 · Expires 2028-01-04 | Direct | 0 |
Reported balance
After 2026-07-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-23 · Exercise / conversion · Disposed 6,260 · Balance 0 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.16 · Expires 2027-05-17 | Direct | 0 |
Reported balance
After 2026-07-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-23 · Exercise / conversion · Disposed 4,440 · Balance 0 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 233,924 |
Reported balance
Holding disclosure · report date 2026-07-23 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 233,924 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2: This is the weighted average sales price representing 4,828 shares sold at prices ranging from $105.09 to $106.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F3: This is the weighted average sales price representing 5,872 shares sold at prices ranging from $106.09 to $106.78 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F4: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
NewAmsterdam Pharma Co N.V.
Report date January 07, 2026 · Filed January 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 10,360 |
Reported balance
After 2026-01-07 transaction · row 1
1 source rowRow 1 · 2026-01-07 · Grant · Acquired 3,400 · Balance 10,360 F1: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. F2: Each RSU was granted on January 7, 2026 for no consideration. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.45 · Expires 2036-01-07 | Direct | 15,300 |
Reported balance
After 2026-01-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-07 · Grant · Acquired 15,300 · Balance 15,300 F3: All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.
F2: Each RSU was granted on January 7, 2026 for no consideration.
F3: All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.
uniQure N.V.
Report date January 27, 2017 · Filed January 31, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.37 · Expires 2027-01-27 | Direct | 11,000 |
Reported balance
After 2017-01-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-27 · Grant · Acquired 11,000 · Balance 11,000 F1: The Stock Option vests 100% on January 27, 2018. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 16,000 |
Reported balance
After 2017-01-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-01-27 · Grant · Acquired 11,000 · Balance 16,000 F2: The Restricted Stock Unit vests 100% on January 27, 2018. F3: Expiration date is not applicable as the vested Restricted Stock Units shall be settled on the first business day following the date that such Restricted Stock Units vests. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Option vests 100% on January 27, 2018.
F2: The Restricted Stock Unit vests 100% on January 27, 2018.
F3: Expiration date is not applicable as the vested Restricted Stock Units shall be settled on the first business day following the date that such Restricted Stock Units vests.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 17, 2022 Filed May 18, 2022 20:07 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 5,996 | $20.18 | $120,999.28 |
DisclosureSEC source: 0001140361-22-019784 · form4.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,828 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F3 · price: This is the weighted average sales price representing the shares sold at prices ranging from $20.07 to $20.24 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| May 16, 2022 Filed May 18, 2022 20:07 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 3,398 | $18.35 | $62,353.30 |
DisclosureSEC source: 0001140361-22-019784 · form4.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,824 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. F2 · price: This is the weighted average sales price representing the shares sold at prices ranging from $18.30 to $18.45 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| May 11, 2022 Filed May 13, 2022 22:13 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 224,450 | $0.00 Strike: $17.07 | $0.00 |
DisclosureSEC source: 0001140361-22-019176 · form4.xml · derivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,450 Underlying: Common Stock · 224,450 shares Expires 2032-05-11 F3 · derivative.exercise_date: Stock options granted under the Company's 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| May 11, 2022 Filed May 13, 2022 22:13 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 47,598 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-019176 · form4.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,222 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on May 11, 2022, for no consideration. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 21:40 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 981 | $0.00 Strike: $16.16 | $0.00 |
DisclosureSEC source: 0001140361-22-011256 · form4.xml · derivative · entry 9 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,614 Underlying: Common Stock · 981 shares Expires 2026-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 21:40 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 65,405 | $0.00 Strike: $16.16 | $0.00 |
DisclosureSEC source: 0001140361-22-011256 · form4.xml · derivative · entry 8 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,595 Underlying: Common Stock · 65,405 shares Expires 2026-01-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 21:40 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 30,228 | $0.00 Strike: $14.24 | $0.00 |
DisclosureSEC source: 0001140361-22-011256 · form4.xml · derivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,228 shares Expires 2023-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 21:40 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 981 | $23.61 | $23,161.41 |
DisclosureSEC source: 0001140361-22-011256 · form4.xml · nonDerivative · entry 6 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,624 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 981 shares sold at prices ranging from $23.61 to $23.64 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 21:40 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 981 | $16.16 | $15,852.96 |
DisclosureSEC source: 0001140361-22-011256 · form4.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 21:40 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 65,405 | $23.16 | $1,514,779.80 |
DisclosureSEC source: 0001140361-22-011256 · form4.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,624 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 65,405 shares sold at prices ranging from $22.61 to $23.60 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 21:40 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 65,405 | $16.16 | $1,056,944.80 |
DisclosureSEC source: 0001140361-22-011256 · form4.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,029 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 21:40 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 30,228 | $23.16 | $700,080.48 |
DisclosureSEC source: 0001140361-22-011256 · form4.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,624 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 30,228 shares sold at prices ranging from $22.62 to $23.61 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| March 23, 2022 Filed Mar 25, 2022 21:40 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 30,228 | $14.24 | $430,446.72 |
DisclosureSEC source: 0001140361-22-011256 · form4.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,852 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 11, 2022 Filed Jan 13, 2022 21:41 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,873 | $25.11 | $72,141.03 |
DisclosureSEC source: 0001140361-22-001607 · form4.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,624 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 06, 2022 Filed Jan 7, 2022 21:25 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 5,337 | $26.00 | $138,762.00 |
DisclosureSEC source: 0001140361-22-000961 · form4.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,756 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 22:06 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 148,540 | $0.00 Strike: $26.43 | $0.00 |
DisclosureSEC source: 0001140361-22-001164 · form4.xml · derivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,540 Underlying: Common Stock · 148,540 shares Expires 2032-01-06 F3 · derivative.exercise_date: Stock options granted under the Company's 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 22:06 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 30,741 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-22-001164 · form4.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,497 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on January 6, 2022, for no consideration. Read SEC document |
| January 05, 2022 Filed Jan 7, 2022 21:25 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 7,126 | $27.61 | $196,748.86 |
DisclosureSEC source: 0001140361-22-000961 · form4.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,093 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units and to cover related broker fees. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 21:08 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 46,614 | $0.00 Strike: $14.24 | $0.00 |
DisclosureSEC source: 0001140361-21-043222 · form4.xml · derivative · entry 9 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,228 Underlying: Common Stock · 46,614 shares Expires 2022-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 21:08 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 46,614 | $27.72 | $1,292,140.08 |
DisclosureSEC source: 0001140361-21-043222 · form4.xml · nonDerivative · entry 6 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,219 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 46,614 shares sold at prices ranging from $27.43 to $28.15 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 27, 2021 Filed Dec 28, 2021 21:08 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 46,614 | $14.24 | $663,783.36 |
DisclosureSEC source: 0001140361-21-043222 · form4.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 21:08 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 46,614 | $0.00 Strike: $14.24 | $0.00 |
DisclosureSEC source: 0001140361-21-043222 · form4.xml · derivative · entry 8 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,842 Underlying: Common Stock · 46,614 shares Expires 2022-10-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 21:08 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 3,386 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001140361-21-043222 · form4.xml · derivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,386 shares Expires 2022-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 21:08 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 46,614 | $28.21 | $1,314,980.94 |
DisclosureSEC source: 0001140361-21-043222 · form4.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,219 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 46,614 shares sold at prices ranging from $27.95 to $28.45 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 21:08 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 46,614 | $14.24 | $663,783.36 |
DisclosureSEC source: 0001140361-21-043222 · form4.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 21:08 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 3,386 | $28.20 | $95,485.20 |
DisclosureSEC source: 0001140361-21-043222 · form4.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,219 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 3,386 shares sold at prices ranging from $28.00 to $28.49 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| December 23, 2021 Filed Dec 28, 2021 21:08 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 3,386 | $3.40 | $11,512.40 |
DisclosureSEC source: 0001140361-21-043222 · form4.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 20:10 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 96,614 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001140361-21-033275 · form4.xml · derivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,386 Underlying: Common Stock · 96,614 shares Expires 2022-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 20:10 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 13,307 | $27.64 | $367,805.48 |
DisclosureSEC source: 0001140361-21-033275 · form4.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,219 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 13,307 shares sold at prices ranging from $27.60 to $27.74 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 20:10 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 83,307 | $27.32 | $2,275,947.24 |
DisclosureSEC source: 0001140361-21-033275 · form4.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,526 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 83,307 shares sold at prices ranging from $26.60 to $27.59 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| September 30, 2021 Filed Oct 1, 2021 20:10 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 96,614 | $3.40 | $328,487.60 |
DisclosureSEC source: 0001140361-21-033275 · form4.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · balance_after: Includes 748 shares acquired through the Company's 2018 Employee Stock Purchase Plan. Read SEC document |
| May 15, 2021 Filed May 18, 2021 20:32 UTC | INSMED Inc INSM · Entity 3174 | Tax withholdingCommon Stock | 6,481 | $26.23 | $169,996.63 |
DisclosureSEC source: 0001140361-21-017888 · form4.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,471 F1 · shares: Shares withheld by the Company to satisfy tax withholding requirements on vesting of time-based restricted stock units. Read SEC document |
| May 12, 2021 Filed May 14, 2021 21:02 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 137,280 | $0.00 Strike: $26.46 | $0.00 |
DisclosureSEC source: 0001140361-21-017456 · form4.xml · derivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,280 Underlying: Common Stock · 137,280 shares Expires 2031-05-12 F3 · derivative.exercise_date: Stock options granted under the Company's 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| May 12, 2021 Filed May 14, 2021 21:02 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 28,344 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-017456 · form4.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,952 F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on May 12, 2021, for no consideration. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 20:22 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001140361-21-009085 · form4.xml · derivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,630 Underlying: Common Stock · 50,000 shares Expires 2022-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 20:22 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 300 | $37.18 | $11,154.00 |
DisclosureSEC source: 0001140361-21-009085 · form4.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,608 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 300 shares sold at prices ranging from $37.05 to $37.25 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 20:22 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 26,061 | $36.66 | $955,396.26 |
DisclosureSEC source: 0001140361-21-009085 · form4.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,908 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 26,061 shares sold at prices ranging from $36.15 to $37.04 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 20:22 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 23,639 | $35.65 | $842,730.35 |
DisclosureSEC source: 0001140361-21-009085 · form4.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,969 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 23,639 shares sold at prices ranging from $35.18 to $36.13 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 20:22 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 50,000 | $3.40 | $170,000.00 |
DisclosureSEC source: 0001140361-21-009085 · form4.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,608 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 21:39 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 109,440 | $0.00 Strike: $34.03 | $0.00 |
DisclosureSEC source: 0001104659-21-002510 · tm211774-11_4seq1.xml · derivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,440 Underlying: Common Stock · 109,440 shares Expires 2031-01-07 F3 · derivative.exercise_date: Stock options granted under the Company's 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| January 07, 2021 Filed Jan 8, 2021 21:39 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 22,039 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-21-002510 · tm211774-11_4seq1.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,608 F1 · shares: Restricted stock units granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the grant. F2 · price: Each Restricted Stock Unit was received as a grant on January 7, 2021, for no consideration, and represents a contingent right to receive one share of Common Stock. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:14 UTC | INSMED Inc INSM · Entity 3174 | Tax withholdingCommon Stock | 2,963 | $33.42 | $99,023.46 |
DisclosureSEC source: 0001104659-21-001607 · tm211774d6_4.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,569 F1 · shares: Shares withheld by the Company to satisfy tax withholding requirements on vesting of time-based restricted stock units. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:11 UTC | INSMED Inc INSM · Entity 3174 | OtherStock Option (right to buy) · Derivative | 245,950 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001104659-21-001601 · tm211774-1_4seq1.xml · derivative · entry 29 Lewis William · CIK 0001402051 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 0 Underlying: Common Stock · 245,950 shares Expires 2026-05-19 F6 · kind: The reported transactions involve transfers of options from the reporting person's spouse to a family trust, ARTICLE 4 TRUST UNDER KATIE PROCTER DYNASTY TRUST, of which the reporting person is a trustee. The reporting person and members of the reporting person's immediate family are the sole beneficiaries of the trust. F2 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:11 UTC | INSMED Inc INSM · Entity 3174 | OtherStock Option (right to buy) · Derivative | 57,000 | $0.00 Strike: $14.24 | $0.00 |
DisclosureSEC source: 0001104659-21-001601 · tm211774-1_4seq1.xml · derivative · entry 25 Lewis William · CIK 0001402051 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 0 Underlying: Common Stock · 57,000 shares Expires 2023-10-31 F6 · kind: The reported transactions involve transfers of options from the reporting person's spouse to a family trust, ARTICLE 4 TRUST UNDER KATIE PROCTER DYNASTY TRUST, of which the reporting person is a trustee. The reporting person and members of the reporting person's immediate family are the sole beneficiaries of the trust. F2 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:11 UTC | INSMED Inc INSM · Entity 3174 | OtherStock Option (right to buy) · Derivative | 67,257 | $0.00 Strike: $12.44 | $0.00 |
DisclosureSEC source: 0001104659-21-001601 · tm211774-1_4seq1.xml · derivative · entry 21 Lewis William · CIK 0001402051 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 0 Underlying: Common Stock · 67,257 shares Expires 2023-05-23 F6 · kind: The reported transactions involve transfers of options from the reporting person's spouse to a family trust, ARTICLE 4 TRUST UNDER KATIE PROCTER DYNASTY TRUST, of which the reporting person is a trustee. The reporting person and members of the reporting person's immediate family are the sole beneficiaries of the trust. F2 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:11 UTC | INSMED Inc INSM · Entity 3174 | OtherStock Option (right to buy) · Derivative | 83,333 | $0.00 Strike: $12.44 | $0.00 |
DisclosureSEC source: 0001104659-21-001601 · tm211774-1_4seq1.xml · derivative · entry 17 Lewis William · CIK 0001402051 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 0 Underlying: Common Stock · 83,333 shares Expires 2023-05-23 F6 · kind: The reported transactions involve transfers of options from the reporting person's spouse to a family trust, ARTICLE 4 TRUST UNDER KATIE PROCTER DYNASTY TRUST, of which the reporting person is a trustee. The reporting person and members of the reporting person's immediate family are the sole beneficiaries of the trust. F5 · derivative.exercise_date: These options became exercisable upon the achievement of certain performance criteria. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 22:11 UTC | INSMED Inc INSM · Entity 3174 | OtherStock Option (right to buy) · Derivative | 83,334 | $0.00 Strike: $12.44 | $0.00 |
DisclosureSEC source: 0001104659-21-001601 · tm211774-1_4seq1.xml · derivative · entry 13 Lewis William · CIK 0001402051 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 0 Underlying: Common Stock · 83,334 shares Expires 2023-05-23 F6 · kind: The reported transactions involve transfers of options from the reporting person's spouse to a family trust, ARTICLE 4 TRUST UNDER KATIE PROCTER DYNASTY TRUST, of which the reporting person is a trustee. The reporting person and members of the reporting person's immediate family are the sole beneficiaries of the trust. F5 · derivative.exercise_date: These options became exercisable upon the achievement of certain performance criteria. Read SEC document |
| January 03, 2021 Filed Jan 6, 2021 22:14 UTC | INSMED Inc INSM · Entity 3174 | Tax withholdingCommon Stock | 4,255 | $33.29 | $141,648.95 |
DisclosureSEC source: 0001104659-21-001607 · tm211774d6_4.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,532 F1 · shares: Shares withheld by the Company to satisfy tax withholding requirements on vesting of time-based restricted stock units. Read SEC document |
| December 30, 2020 Filed Jan 6, 2021 22:11 UTC | INSMED Inc INSM · Entity 3174 | GiftStock Option (right to buy) · Derivative | 245,950 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001104659-21-001601 · tm211774-1_4seq1.xml · derivative · entry 28 Lewis William · CIK 0001402051 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 245,950 Underlying: Common Stock · 245,950 shares Expires 2026-05-19 F4 · kind: The reported transactions involve a gift of securities by the reporting person to his spouse. F2 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| December 30, 2020 Filed Jan 6, 2021 22:11 UTC | INSMED Inc INSM · Entity 3174 | GiftStock Option (right to buy) · Derivative | 245,950 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001104659-21-001601 · tm211774-1_4seq1.xml · derivative · entry 27 Lewis William · CIK 0001402051 · Director · Chair & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 245,950 shares Expires 2026-05-19 F4 · kind: The reported transactions involve a gift of securities by the reporting person to his spouse. F2 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.